Mufg Securities Americas Inc. Buys 6,126 Shares of Medtronic PLC $MDT

Mufg Securities Americas Inc. increased its position in Medtronic PLC (NYSE:MDT) by 21.6% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 34,551 shares of the medical technology company’s stock after purchasing an additional 6,126 shares during the quarter. Mufg Securities Americas Inc.’s holdings in Medtronic were worth $3,291,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. AXQ Capital LP grew its position in Medtronic by 25.6% in the 2nd quarter. AXQ Capital LP now owns 9,890 shares of the medical technology company’s stock worth $862,000 after purchasing an additional 2,013 shares during the period. UMB Bank n.a. lifted its holdings in shares of Medtronic by 65.8% during the 3rd quarter. UMB Bank n.a. now owns 138,278 shares of the medical technology company’s stock valued at $13,170,000 after buying an additional 54,898 shares during the period. Applied Finance Capital Management LLC purchased a new position in shares of Medtronic in the 3rd quarter worth $1,308,000. Willis Investment Counsel grew its holdings in shares of Medtronic by 5.0% in the third quarter. Willis Investment Counsel now owns 401,868 shares of the medical technology company’s stock worth $38,274,000 after acquiring an additional 19,192 shares during the period. Finally, Principal Financial Group Inc. grew its holdings in shares of Medtronic by 17.2% in the third quarter. Principal Financial Group Inc. now owns 1,656,155 shares of the medical technology company’s stock worth $157,732,000 after acquiring an additional 242,910 shares during the period. 82.06% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

MDT has been the topic of several analyst reports. Sanford C. Bernstein lifted their price target on shares of Medtronic from $111.00 to $112.00 and gave the stock an “outperform” rating in a research note on Friday, January 9th. JPMorgan Chase & Co. dropped their price target on Medtronic from $105.00 to $100.00 and set a “neutral” rating for the company in a research note on Wednesday, February 18th. Citigroup assumed coverage on shares of Medtronic in a research report on Tuesday, February 3rd. They set a “buy” rating and a $117.00 price objective on the stock. Wall Street Zen raised shares of Medtronic from a “hold” rating to a “buy” rating in a report on Saturday. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Medtronic in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $110.84.

Key Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Received CE mark for its next‑gen GI Genius module and ColonPRO software — expands regulatory clearance and commercial runway in GI imaging, a clear revenue catalyst. Medtronic wins CE mark for next-gen GI Genius module, ColonPRO software
• Positive Sentiment: Recognized at the 2026 Dorian Awards for structured problem‑solving excellence — a reputational boost that supports brand value with hospitals and enterprise customers. 2026 DORIAN AWARDS RECOGNIZE GLOBAL LEADERS IN STRUCTURED PROBLEM-SOLVING EXCELLENCE
• Positive Sentiment: Multiple investor pieces highlight Medtronic’s strong dividend profile and defensive cash flows, reinforcing interest from income-seeking investors and supporting the share price floor. 1 Reason I’d Buy Medtronic Stock and Never Sell
• Neutral Sentiment: BTIG maintained a Hold rating on MDT — not bearish but keeps analyst sentiment from turning strongly positive. BTIG Sticks to Its Hold Rating for Medtronic (MDT)
• Neutral Sentiment: Valuation/returns analysis pieces point to mixed long‑term returns and prompt investors to reassess fair value — supports trading volatility but not a clear directional signal. Is It Time To Reconsider Medtronic (MDT) After Mixed Long Term Share Returns
• Neutral Sentiment: Industry podcast and revenue roundups highlight broader medtech winners from 2025 — useful context for sector positioning but not company‑specific catalysts. Podcast: Which pharma and medtech companies came out on top in 2025 revenues?
• Neutral Sentiment: Coverage of broader trade/tariff uncertainty underscores a macro risk — CEOs want policy clarity, which could affect multinational supply chains and sentiment for global medtech firms like Medtronic. Veteran CEO: President Trump’s chaotic tariff policy is not working

Medtronic Price Performance

Shares of Medtronic stock opened at $98.54 on Tuesday. The stock has a market cap of $126.33 billion, a price-to-earnings ratio of 27.45, a price-to-earnings-growth ratio of 2.43 and a beta of 0.71. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42. The stock has a 50 day moving average price of $99.03 and a 200-day moving average price of $96.80. Medtronic PLC has a one year low of $79.55 and a one year high of $106.33.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. Medtronic had a return on equity of 14.88% and a net margin of 13.00%.The company had revenue of $9.02 billion during the quarter, compared to the consensus estimate of $8.89 billion. During the same period last year, the company earned $1.38 earnings per share. Medtronic’s revenue was up 5.8% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities analysts expect that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 16th. Investors of record on Friday, December 26th were given a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend was Friday, December 26th. Medtronic’s dividend payout ratio is 79.11%.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).